- Home
- WLYB vs CPRX Comparison
WLYB vs CPRX Comparison
Compare WLYB & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- CPRX
- Stock Information
- Founded
- WLYB 1807
- CPRX 2002
- Country
- WLYB United States
- CPRX United States
- Employees
- WLYB N/A
- CPRX N/A
- Industry
- WLYB Books
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- CPRX Health Care
- Exchange
- WLYB Nasdaq
- CPRX Nasdaq
- Market Cap
- WLYB 2.7B
- CPRX 2.8B
- IPO Year
- WLYB N/A
- CPRX 2006
- Fundamental
- Price
- WLYB $51.93
- CPRX $20.60
- Analyst Decision
- WLYB
- CPRX Strong Buy
- Analyst Count
- WLYB 0
- CPRX 6
- Target Price
- WLYB N/A
- CPRX $30.50
- AVG Volume (30 Days)
- WLYB 193.0
- CPRX 1.0M
- Earning Date
- WLYB 12-04-2024
- CPRX 11-06-2024
- Dividend Yield
- WLYB 2.68%
- CPRX N/A
- EPS Growth
- WLYB N/A
- CPRX 114.68
- EPS
- WLYB N/A
- CPRX 1.18
- Revenue
- WLYB $1,825,783,000.00
- CPRX $460,482,000.00
- Revenue This Year
- WLYB N/A
- CPRX $21.99
- Revenue Next Year
- WLYB $1.12
- CPRX $17.95
- P/E Ratio
- WLYB N/A
- CPRX $17.48
- Revenue Growth
- WLYB N/A
- CPRX 32.17
- 52 Week Low
- WLYB $28.35
- CPRX $13.00
- 52 Week High
- WLYB $52.58
- CPRX $24.27
- Technical
- Relative Strength Index (RSI)
- WLYB 69.63
- CPRX 39.71
- Support Level
- WLYB $49.30
- CPRX $21.30
- Resistance Level
- WLYB $52.29
- CPRX $24.27
- Average True Range (ATR)
- WLYB 0.08
- CPRX 0.79
- MACD
- WLYB 0.16
- CPRX -0.18
- Stochastic Oscillator
- WLYB 88.77
- CPRX 4.18
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.